These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 30511789)

  • 21. Adjuvant therapy use among Appalachian breast cancer survivors.
    Tan X; Marshall VD; Anderson RT; Donohoe J; Camacho F; Balkrishnan R
    Medicine (Baltimore); 2015 Jul; 94(26):e1071. PubMed ID: 26131828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized Controlled Pilot Trial of a Low-Touch Remotely-Delivered Values Intervention to Promote Adherence to Adjuvant Endocrine Therapy Among Breast Cancer Survivors.
    Arch JJ; Crespi CM; Levin ME; Genung SR; Nealis M; Mitchell JL; Bright EE; Albright K; Magidson JF; Stanton AL
    Ann Behav Med; 2022 Aug; 56(8):856-871. PubMed ID: 35323853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases.
    Lambert-Côté L; Bouhnik AD; Bendiane MK; Bérenger C; Mondor M; Huiart L; Lauzier S
    Breast Cancer Res Treat; 2020 Apr; 180(3):777-790. PubMed ID: 32086655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of a community pharmacy-based intervention to enhance adherence to adjuvant endocrine therapy among breast cancer survivors guided by the Intervention Mapping approach.
    Labonté M; Guillaumie L; Dionne A; Dorval M; Nabi H; Lemieux J; Provencher L; Lauzier S
    Res Social Adm Pharm; 2020 Dec; 16(12):1724-1736. PubMed ID: 32205070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Are breast cancer patients with suboptimal adherence to cardiovascular treatment more likely to discontinue adjuvant endocrine therapy? Competing risk survival analysis in a nationwide cohort of postmenopausal women.
    Artignan J; Capmas P; Panjo H; Constantinou P; Pelletier-Fleury N
    BMC Med; 2023 Nov; 21(1):463. PubMed ID: 38001491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Persistence and discontinuation of adjuvant endocrine therapy in women with breast cancer.
    Kuba S; Ishida M; Nakamura Y; Taguchi K; Ohno S
    Breast Cancer; 2016 Jan; 23(1):128-133. PubMed ID: 24934610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Initiation and adherence to adjuvant endocrine therapy among urban, insured American Indian/Alaska Native breast cancer survivors.
    Emerson MA; Achacoso NS; Benefield HC; Troester MA; Habel LA
    Cancer; 2021 Jun; 127(11):1847-1856. PubMed ID: 33620753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor-Positive Breast Cancer.
    Hu X; Walker MS; Stepanski E; Kaplan CM; Martin MY; Vidal GA; Schwartzberg LS; Graetz I
    JAMA Netw Open; 2022 Aug; 5(8):e2225485. PubMed ID: 35947386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Race and Patient-reported Symptoms in Adherence to Adjuvant Endocrine Therapy: A Report from the Women's Hormonal Initiation and Persistence Study.
    Sheppard VB; Sutton AL; Hurtado-de-Mendoza A; He J; Dahman B; Edmonds MC; Hackney MH; Tadesse MG
    Cancer Epidemiol Biomarkers Prev; 2021 Apr; 30(4):699-709. PubMed ID: 33514603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The experiences of adjuvant endocrine therapy for women breast cancer survivors: A literature review.
    Long Y; Xie S; Liu Q; Xu F; Li Q; Wang N; Zhang Y
    Medicine (Baltimore); 2023 Dec; 102(51):e36704. PubMed ID: 38134074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Previous Medication Regimen Factors and Bipolar and Psychotic Disorders on Breast Cancer Endocrine Therapy Adherence.
    Haskins CB; Neuner JM; McDowell BD; Carnahan RM; Fiedorowicz JG; Wallace RB; Smith BJ; Chrischilles EA
    Clin Breast Cancer; 2020 Jun; 20(3):e261-e280. PubMed ID: 32139273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A telehealth intervention for symptom management, distress, and adherence to adjuvant endocrine therapy: A randomized controlled trial.
    Jacobs JM; Post K; Massad K; Horick NK; Walsh EA; Cohn J; Rapoport CS; Clara AJ; Antoni MH; Safren SA; Partridge AH; Peppercorn JM; Park ER; Temel JS; Greer JA
    Cancer; 2022 Oct; 128(19):3541-3551. PubMed ID: 35924869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical factors associated with patterns of endocrine therapy adherence in premenopausal breast cancer patients.
    Woolpert KM; Schmidt JA; Ahern TP; Hjorth CF; Farkas DK; Ejlertsen B; Collin LJ; Lash TL; Cronin-Fenton DP
    Breast Cancer Res; 2024 Apr; 26(1):59. PubMed ID: 38589932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence.
    Lee C; Check DK; Manace Brenman L; Kushi LH; Epstein MM; Neslund-Dudas C; Pawloski PA; Achacoso N; Laurent C; Fehrenbacher L; Habel LA
    Breast Cancer Res Treat; 2020 Feb; 180(1):219-226. PubMed ID: 31975315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Patient's Voice: Adherence, Symptoms, and Distress Related to Adjuvant Endocrine Therapy After Breast Cancer.
    Jacobs JM; Walsh EA; Park ER; Berger J; Peppercorn J; Partridge A; Horick N; Safren SA; Temel JS; Greer JA
    Int J Behav Med; 2020 Dec; 27(6):687-697. PubMed ID: 32495240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Behavioral Interventions to Enhance Adherence to Hormone Therapy in Breast Cancer Survivors: A Systematic Literature Review.
    Hurtado-de-Mendoza A; Cabling ML; Lobo T; Dash C; Sheppard VB
    Clin Breast Cancer; 2016 Aug; 16(4):247-255.e3. PubMed ID: 27133733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. THRIVE study protocol: a randomized controlled trial evaluating a web-based app and tailored messages to improve adherence to adjuvant endocrine therapy among women with breast cancer.
    Paladino AJ; Anderson JN; Krukowski RA; Waters T; Kocak M; Graff C; Blue R; Jones TN; Buzaglo J; Vidal G; Schwartzberg L; Graetz I
    BMC Health Serv Res; 2019 Dec; 19(1):977. PubMed ID: 31856812
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sociodemographic, clinical, psychosocial, and healthcare-related factors associated with beliefs about adjuvant endocrine therapy among breast cancer survivors.
    Sutton AL; Salgado TM; He J; Hurtado-de-Mendoza A; Sheppard VB
    Support Care Cancer; 2020 Sep; 28(9):4147-4154. PubMed ID: 31897782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors Influencing Adherence to Adjuvant Endocrine Therapy After Breast Cancer Surgery.
    Johnsson A; von Wachenfeldt A
    Cancer Rep (Hoboken); 2024 Aug; 7(8):e2160. PubMed ID: 39158164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of patient subgroups who benefit from a behavioral intervention to improve adjuvant endocrine therapy adherence: a randomized-controlled trial.
    Walsh EA; Post K; Massad K; Horick N; Antoni MH; Penedo FJ; Safren SA; Partridge AH; Peppercorn J; Park ER; Temel JS; Greer JA; Jacobs JM
    Breast Cancer Res Treat; 2024 Apr; 204(3):547-559. PubMed ID: 38231313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.